TB-500 vs CJC-1295
A comprehensive, data-driven comparison of TB-500 (Thymosin Beta-4) and CJC-1295 (Modified GRF 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | TB-500 Thymosin Beta-4, Tβ4 | CJC-1295 Modified GRF 1-29, DAC:GRF |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Category 2 (pending reclassification) |
| Category | Recovery & Healing | Growth Hormone |
| Primary Use | Tissue repair and injury recovery | Growth hormone optimization and anti-aging |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $40 - $80/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2-5mg twice weekly | 1-2mg twice weekly (with DAC) |
| Frequency | Twice weekly | Twice weekly |
| Mechanism | Synthetic version of thymosin beta-4 that promotes cell migration, reduces inflammation, and accelerates wound healing | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Low | Emerging |
| Clinical Trial Phase | N/A | N/A |
Key Differences
- 1CJC-1295 is generally more affordable ($35 - $70/mo) compared to TB-500 ($40 - $80/mo).
- 2TB-500 has low-quality evidence, while CJC-1295 has emerging-quality evidence.
- 3They belong to different categories: TB-500 (Recovery & Healing) vs CJC-1295 (Growth Hormone).
Which Is Better For...
CJC-1295
More budget-friendly option with lower monthly costs
TB-500
Fewer commonly reported side effects
TB-500
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| TB-500 | $40 - $80/mo | Category 2 (pending reclassification) | Various research labs |
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
TB-500 works via Synthetic version of thymosin beta-4 that promotes cell migration, reduces inflammation, and. CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. They differ in FDA approval status, efficacy data, and cost.
TB-500 typically costs $40 - $80/mo, while CJC-1295 costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
TB-500 is not FDA-approved (Category 2 (pending reclassification)). CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of TB-500 include Injection site reactions, Mild fatigue, Headache. Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which plays a crucial role in tissue repair and regeneration. It promotes the migration of endothelial and keratinocyt...
View Full TB-500 GuideCJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between TB-500 and CJC-1295 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.